Special Issue

Emerging Issues in COVID Vaccine

Message from the Guest Editors

The time has come to summarize the effectiveness of vaccines over the last 12 months, especially in the context of the emergence of new variants and the expansion of vaccination schedules with new doses. Factors (especially biochemical and genetic) determining the course of COVID-19 as well as those responsible for the intensity of the immune system's response to vaccinations are still being sought. We still know too little about genetic determinants (such as changes in the gene expression profile, the presence of polymorphisms or epigenetic regulations) of the immune response to SARS-CoV-2-related antigens.Let us summarize the role of vaccination in reducing the negative effects of a pandemic and in assessing the immune response in the rational management of vaccination programs together.

Guest Editors

Dr. Francesco Bianco

Department of Neurosciences, Imaging and Clinical Sciences, "G. d'Annunzio" of Chieti-Pescara, Via dei Vestini, 66100 Chieti, Italy

Dr. Joanna Szczepanek

Centre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, UI. Wilenska 4, 87-100 Torun, Poland

Deadline for manuscript submissions

closed (30 September 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/116477

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).